Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan
Blood Vessels, Thrombosis & Hemostasis · 2024-12 · 1 (4) · 100027
DOI: 10.1016/j.bvth.2024.100027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2024-12. Verfasst von Daichi Kishi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kobe City Medical Center General Hospital.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Förderung
- Kobe City Medical Center General Hospital
Zitieren
APA
Kishi, D., Nishikubo, M., Shimomura, Y., Ishikawa, T., & Kondo, T. (2024). Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan. Blood Vessels, Thrombosis & Hemostasis, 1(4), 100027. https://doi.org/10.1016/j.bvth.2024.100027
Vancouver
Kishi D, Nishikubo M, Shimomura Y, Ishikawa T, Kondo T. Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan. Blood Vessels, Thrombosis & Hemostasis. 2024;1(4):100027. doi:10.1016/j.bvth.2024.100027
BibTeX
@article{Kishi2024,
author = {Kishi, Daichi and Nishikubo, Masashi and Shimomura, Yoshimitsu and Ishikawa, Takayuki and Kondo, Tadakazu},
title = {Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2024},
volume = {1},
number = {4},
pages = {100027},
doi = {10.1016/j.bvth.2024.100027}
}
EUVIMED